E.N. SHAROVA, M.V. ZLOKAZOVA

Kirov State Medical University, 112 Karl Marks Str., Kirov, Russian Federation, 610000 

Sharova E.N. — Lecturer of the Department of Psychology and Pedagogy, tel. +7-912-820-10-93, e-mail: [email protected]

Zlokazova M.V. — D. Med. Sc., Professor of the Department of Psychiatry named after V.I. Bagaev, tel. (8332) 55-75-11, e-mail: [email protected]

The article analyzes data on psychiatric (psychotic) effects of new «designer drugs». The practical examples show the effects of the above drugs which destroy psyche, cause dangerous actions, damages, events and psychotic disorders that occurred during consumption of synthetic cannabic substances in smoking mixtures of «spice» types. Facts are shown of toxic and narcogenic effects of psychic stimulators called «salts» by drug abusers. Somatovegetative and psychic disorders are revealed in drug abusers. Problems and necessity of more thorough investigations of psychic disorders in drug abusers of modern cannabic substances and psychic stimulators are shown.

Key words: cannabic substances, «spices», psychic stimulators, «salts», drug abusers, psychiatric (psychotic) disorders, designer drugs.

REFERENCES

1. Mendelevich V.D. sychotic disorders as a result of drug use. Narkologiya, 2014, no. 7, pp. 93-100 (in Russ.).
2. Mezhdunarodnaya statisticheskaya klassifikatsiya bolezney i problem, svyazannykh so zdorov’em (MKB-10). Psikhicheskie i povedencheskie rasstroystva [International Statistical Classification of Diseases and Related Health Problems (ICD-10). Mental and behavioral disorders]. Saint Petersburg, 1994. 304 p.
3. Warner L.A., Kessler, R.C., Hughes, M. et al. Prevalence and correlates of drug use and dependence in the United States. Results from the National Comorbidity. Survey. Arch. Gen. Psychiatr, 1995, vol. 52, pp. 219-229.
4. Castaneto M.S., Gorelick D.A., Desrosiers N.A., et al. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug and Alcohol Dependence, 2014, Nov 1, 144, pp. 12-41.
5. Niemi-Pynttari J.A., Sund R., Putkonen H. et al. Substance-induced psychoses converting into schizophrenia: a register- based study of 18,478 Finnish inpatient cases. J. Clin. Psychiatry, 2013, vol. 74 (1), pp. 94-99.
6. Golovko A.I., Sofronov A.G., Sofronov G.A. The new banned cannabinoids. Neurochemistry and neurobiology. The biological activity of synthetic cannabinoids, first identified in illicit trafficking for the period 2011-2013. Narkologiya, 2010, no. 7, pp. 68-83 (in Russ.).
7. Sofronov G.A., Golovko A.I. et al. Synthetic cannabinoids. The state of the problem. Narkologiya, 2012, no. 10, pp. 97-110 (in Russ.).
8. Chukhrova M.G., Pronin S.V., Ivanova V.E. Psychic and psychosomatic consequences of consumption of spice. Mir nauki, kul’tury, obrazovaniya, 2015, no. 1, pp. 50 (in Russ.).
9. Ivanyuzhenko N.D., Volchkova A.N. Disorder of the psyche with the use of smoking mixtures. Tyumenskiy meditsinskiy zhurnal, 2010, no. 1 (in Russ.).
10. Moore T.H., Zammit S., Lingford-Hughes A., et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet, 2007, vol. 370, no. 9584, pp. 319-328.
11. Entsiklopediya narkotikov, Dizaynerskie (sinteticheskie), Mefedron ― novyy dizaynerskiy narkotik [Encyclopedia of drugs. Designer (synthetic). Mefedron — a new designer drug], avaialable at: http://netnarkotiki.ru/entsiklopediya-narkotikov/dizaynerskie-sinteticheskie/mefedron.html
12. Dargan P., Wood D. Novel recreational drugs and “Legal Highs” over the last five years. J. Med. Toxicol, 2010; early online publications.
13. Kehr J., Ichinose F., Yoshitake S., et al. Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. Br. J. Pharmacol, 2011, Dec, 164 (8), pp. 1949-58.